NasdaqGM - Nasdaq Real Time Price USD

Alvotech (ALVO)

11.22

-0.22

(-1.97%)

At close: June 2 at 4:00:00 PM EDT

11.22

0.00

(0.00%)

After hours: June 2 at 4:04:02 PM EDT

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with re

GlobeNewswire 18 hours ago

ALVO
-1.97%

ALVOW
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa

GlobeNewswire 5 days ago

ALVO
-1.97%

ALVOW
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider services to ensure liquidity in the Company’s Swedish Depository Receipts (“SDRs”), equity share equivalents, trading on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm’s rules on liquidity providers. In the role of liquidity provider, DNB Carn

GlobeNewswire 15 days ago

ALVO
-1.97%

ALVOW
Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — On May 16, 2025 Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, an

GlobeNewswire 15 days ago

ALVO
-1.97%

ALVOW
Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 16, 2025) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces th

GlobeNewswire 17 days ago

ALVO
-1.97%

ALVOW
There May Be Underlying Issues With The Quality Of Alvotech's (NASDAQ:ALVO) Earnings

Alvotech ( NASDAQ:ALVO ) just reported some strong earnings, and the market reacted accordingly with a healthy uplift...

Simply Wall St. 18 days ago

ALVO
-1.97%

ALVOW
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report

It's been a pretty great week for Alvotech ( NASDAQ:ALVO ) shareholders, with its shares surging 18% to US$9.68 in the...

Simply Wall St. 23 days ago

ALVO
-1.97%

ALVOW
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2

GlobeNewswire 24 days ago

ALVO
-1.97%

ALVOW
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 8, 2025) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wor

GlobeNewswire 26 days ago

ALVO
-1.97%

ALVOW
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $2

GlobeNewswire 26 days ago

ALVO
-1.97%

ALVOW
Exploring High Growth Tech Stocks In The US Market

In the current landscape of the United States market, investors are closely monitoring mixed stock performances as they await key announcements such as the Federal Reserve's interest rate decision and developments in trade negotiations with China. Amid this backdrop, high growth tech stocks continue to capture attention for their potential to thrive despite economic uncertainties, making them a focal point for those seeking opportunities in an evolving market environment.

Simply Wall St. 26 days ago

AGYS

ALVO
-1.97%

ALVOW
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company’s product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currentl

GlobeNewswire 26 days ago

ALVO
-1.97%

ALVOW
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025SELARSDI is approved for all indications matching the reference productSELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to seve

GlobeNewswire 28 days ago

TEVA

TEVJF

ALVO
-1.97%
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio o

GlobeNewswire last month

ALVO
-1.97%

ALVOW
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at

GlobeNewswire last month

ALVO
-1.97%

ALVOW
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a mediocre week for Alvotech ( NASDAQ:ALVO ) shareholders, with the stock dropping 17% to US$9.55 in the week...

Simply Wall St. 2 months ago

ALVO
-1.97%

ALVOW
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Alvotech ( NASDAQ:ALVO ) Full Year 2024 Results Key Financial Results Revenue: US$492.0m (up 427% from FY 2023). Net...

Simply Wall St. 2 months ago

ALVO
-1.97%

ALVOW
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty

GlobeNewswire 2 months ago

ALVO
-1.97%

ALVOW
Alvotech Reports Record Results for 2024 and Provides Business Update

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a business update conference call a

GlobeNewswire 2 months ago

ALVO
-1.97%

ALVOW
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announ

GlobeNewswire 2 months ago

ALVO
-1.97%

ALVOW

Performance Overview

Return	ALVO	S&P 500 (^GSPC)
YTD	-15.23%	+0.92%
1-Year	-19.20%	+12.48%
3-Year	+18.05%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alvotech (ALVO)

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today

Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm

There May Be Underlying Issues With The Quality Of Alvotech's (NASDAQ:ALVO) Earnings

Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report

Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

Exploring High Growth Tech Stocks In The US Market

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets

Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech Reports Record Results for 2024 and Provides Business Update

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Performance Overview